Direct Acting Antiviral and Glycemic Control In Patients with Hepatitis C
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 10, Pages 1426-1435
AbstractBackground sustained virological response (SVR) can be achieved in high percentage of HCV patients with the availability of direct acting antiviral agents DAAs. However, the effect of DAAs on insulin resistance and glycemic control has to be clearly documented in patients with HCV infection and type 2diabtes mellitus.
We hypothesize that treatment of HCV with novel direct-acting antiviral medications may have effect on glycemic control and decreased requirement for DM-modulating medications at the time of SVR.
Patients and methods: the present study involved 50 patients with Chronic HCV attended to outpatient hepatology clinic of One Day Surgery Hospital for treatment with DAAs. Measurement of HbA1c, FPG, fasting insulin hormone, c-peptide and calculation of HOMA-IR before and 3 months after DDAs therapy is done.
Statistical analysis was done for these data. Results : After achievement of SVR; HbA1c decreased from 9.57±1.39 to 7.22 ± 0.7 in diabetic patients, HOMA-IR decreased significantly also there was a significant improvement of lipid profile after completion of therapy.
Conclusion: This study showed that eradication of HCV by DAAs cause a parallel decrease in IR and improve glycemic control in patients with established T2DM.
- Article View: 121
- PDF Download: 214